Valo Health Inc. has disclosed tricyclic phthalazinone compounds acting as poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
When life-saving inhalers sell in Europe at 1.5% to about 8% of their list price in the U.S., they’re bound to attract scrutiny, especially in a time when inequities in prescription drug prices are fueling more and more legislation to reduce U.S. prices.
Vaxess Technologies Inc. seeks patent protection for devices that enable the reliable application of silk fibroin-based microneedle medicament patches used for delivering small molecule drugs, vaccines, peptides, biologics, antibodies, hormones or other materials into or through the skin.
Monte Rosa Therapeutics Inc. has described molecular glue degraders comprising cereblon ligands and a casein kinase 1 Isoform α (CK1α) targeting moiety acting as CK1α degradation inducers reported to be useful for the treatment of cancer.
Researchers at Jiangsu Hengrui Medicine Co. Ltd., Shanghai Fourth People’s Hospital Affiliated Tongji University and Shanghai Senhui Pharmaceutical Co. Ltd. have divulged cyclopentyl adenosine derivatives reported to be useful for the treatment of chronic pain.
Researchers from Florey Neuroscience Institutes, Monash University and Olivia Newton-John Cancer Research Institute have identified fluorine-radiolabeled compounds acting as tyrosine-protein kinase Mer (MERTK) inhibitors and also as positron emission tomography (PET) imaging agents reported to be useful for the diagnosis and treatment of multiple sclerosis (MS).
The U.S. Patent and Trademark Office’s inter partes review mechanism has drawn uneven reviews in the past decade or so and Dexcom Inc. has serious misgivings about an attempt by Abbott Diabetes Care Inc. to use the process to invalidate Dexcom patents for continuous glucose monitors.
Dr. Pfleger Arzneimittel GmbH is seeking patent protection for a system and a corresponding computer program product for assisting in alleviating overactive bladder syndrome and incontinence symptoms, particularly reduction of micturitions and reduction of urine loss. The system is particularly suited for being implemented and distributed as a smartphone app which may be operated by the user.
RSS
